FIG 2.

Therapeutic efficacy of LSEVh-LS-F in rhesus macaques during SHIV acute infection. (A) Experimental design of therapy experiment during the acute phase of SHIV infection. Eight rhesus macaques were challenged intravenously with SHIV_SF162P3 (1,000 TCID₅₀) and treated with 10 mg/kg of LSEVh-LS-F or PBS (n = 4 per group) on days 7, 9, 16, and 18. Plasma was collected at different time points (days 0, 7, 9, 16, 18, 21, 25, and 30). The orange arrows indicate the day of LESVh-LS-F administration. (B) Comparison of normalized plasma viral load (pVL) change at each time point, as determined by an unpaired two-tailed t test on log-transformed data. The error bars represent SDs for each group. (C) Data fitting for untreated macaques with mathematical models. Four constants were defined by data fitting: ku, k, T, and SHIV₀. Initial SHIV₀ load values and time of the viremia peak are shown by dashed lines. (D) Data fitting for treated macaques. Five constants were defined for each macaque by data fittings: kt, k7, k9, k16, and k18. SHIV₀ was fixed as the average value for untreated macaques.